CP-097

DOSE ADJUSTMENT OF TENOFOVIR IN HIV-PATIENTS WITH RENAL IMPAIRMENT

Vázquez-Sánchez R, Rodríguez-Quesada P, López Esteban L, Ramón-García J, Sánchez Rubio-Ferrández J, Molina García T.
Hospital Universitario de Getafe, Madrid, Spain

BACKGROUND

Use of TDF may be associated with renal toxicity and it is recommended to tailor the dose in patients with CrCl<50mL/min.



PURPOSE

➢To determine the prevalence rate of patients with CrCl<50mL/min receiving TDF.

➢To evaluate whether dose adjustment is properly performed according to the recommendations.

METHODS

Retrospective/observational study (January 2010 - December 2012)

Inclusion criteria:
> 6 months with TDF
baseline normal CrCl
three CrCl determinations

Potential risk factors
age/gender
baseline CD4/HIV-RNA
co-formulated presentation
previous therapies/comorbidities

➢CrCl was calculated using the MDRD formula.

➢GESIDA guide recommendations:

CrCl<50mL/min → 300mg/48h

CrCl<30mL/min → 300mg/72-96h

1 2 3 4

RESULTS

n=451 patients

♂=68.2%

age=46.2±8.2 years

➢Treatment lines prior TDF : 2.4 ± 2.1

➢Use of co-formulated TDF-presentation: 100% of patients

➢CrCl<50mL/min: 4.8% of patients

(14% of them CrCl<30 mL/min)

Dose modifications according to recommendations: 0% of patients

Change to TDF free combination: 40% of patients

CONCLUSIONS

➢Patients on treatment with TDF need a dose adjustment due to renal impairment rarely. Moreover, dose adjustment was not performed in any case of renal impairment, while therapy change is preferred.

Conflict of interest: Nothing to disclose

Email: rocio.vazquez@salud.madrid.org

20th Congress of European Association of Hospital Pharmacists. 25th-27th March 2015, Hamburg, Germany